Research programme: CAR T cells therapeutics - Jecho Biotechnology
Latest Information Update: 07 Nov 2024
Price :
$50 *
At a glance
- Originator JECHO Biopharmaceuticals
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Solid tumours